Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Hereditary Sensory and Autonomic Neuropathies 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Fulvestrant 4serabelisib 2sapanisertib 2ribociclib 2palbociclib 2tivozanib 1pembrolizumab 1olaparib 1exemestane 1abemaciclib 1Tamoxifen 1Secretin 1STX-478 1Radiotherapy 1Pharmaceutical Preparations 1Paclitaxel 1Nivolumab 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Carboplatin 1CA-19-9 Antigen 1Anastrozole 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hereditary Sensory and Autonomic Neuropathies × tivozanib × Clear all
NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡